» Articles » PMID: 35209940

Therapeutic Efficacy of Mesenchymal Stem Cells for Abdominal Aortic Aneurysm: a Meta-analysis of Preclinical Studies

Overview
Publisher Biomed Central
Date 2022 Feb 25
PMID 35209940
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Abdominal aortic aneurysm (AAA) is life-threatening, surgical treatment is currently the only clinically available intervention for the disease. Mesenchymal stem cells (MSCs) have presented eligible immunomodulatory and regenerative abilities which showed favorable therapeutic efficacy in various cardiovascular diseases. However, current evidence summarizing the effectiveness of MSCs for AAA is lacking. Thus, a meta-analysis and systematic review was necessary to be performed to assess the therapeutic efficacy of MSCs for AAA in preclinical studies.

Methods: Comprehensive literature search restricted in English was conducted in PubMed, Cochrane Library, EBSCO, EMBASE and Web of Science from inception to Oct 2021. The primary outcomes were parameters about aortic diameter change during MSCs intervention. The secondary outcomes included elastin content and expression level of inflammatory cytokines, matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). Data were extracted and analyzed independently by two authors. The meta package with random effects model was used to calculate the pooled effect size and 95% confidence intervals in R (version 4.0.2).

Results: Meta-analysis of 18 included studies demonstrated that MSCs intervention has significant therapeutic effects on suppressing aortic diameter enlargement compared with the control group (diameter, SMD = - 1.19, 95% CI [- 1.47, - 0.91]; diameter change ratio, SMD = - 1.36, 95% CI [- 1.72, - 1.00]). Subgroup analysis revealed differences between MSCs and control group regarding to cell type, intervention route and cell compatibility. Moreover, the meta-analysis also showed that MSCs intervention had a significant effect on preserving aortic elastin content, reducing MCP-1, TNF-α, IL-6, MMP-2/9 and increasing TIMP-1/2 expression level compared with control group.

Conclusion: Our results suggested that MSC intervention is effective in AAA by suppressing aortic diameter enlargement, reducing elastin degradation, and modulating local immunoinflammatory reactions. These results are important for the systemic application of MSCs as a potential treatment candidate for AAA in further animal experiments and clinical trials.

Citing Articles

New Trends of Personalized Medicine in the Management of Abdominal Aortic Aneurysm: A Review.

Alsabbagh Y, Erben Y, Vandenberg J, Farres H J Pers Med. 2024; 14(12).

PMID: 39728062 PMC: 11677056. DOI: 10.3390/jpm14121148.


A Single Injection of ADRCs Does Not Prevent AAA Formation in Rats in a Randomized Blinded Design.

Kavaliunaite E, Dhumale P, Jensen C, Sheikh S, Lindholt J, Stubbe J Int J Mol Sci. 2024; 25(14).

PMID: 39062833 PMC: 11276694. DOI: 10.3390/ijms25147591.


Promising Novel Therapies in the Treatment of Aortic and Visceral Aneurysms.

Stougiannou T, Christodoulou K, Georgakarakos E, Mikroulis D, Karangelis D J Clin Med. 2023; 12(18).

PMID: 37762818 PMC: 10531975. DOI: 10.3390/jcm12185878.


Novel pharmacological approaches in abdominal aortic aneurysm.

Puertas-Umbert L, Almendra-Pegueros R, Jimenez-Altayo F, Sirvent M, Galan M, Martinez-Gonzalez J Clin Sci (Lond). 2023; 137(15):1167-1194.

PMID: 37559446 PMC: 10415166. DOI: 10.1042/CS20220795.


Smooth Muscle Heterogeneity and Plasticity in Health and Aortic Aneurysmal Disease.

Hu Y, Cai Z, He B Int J Mol Sci. 2023; 24(14).

PMID: 37511460 PMC: 10380637. DOI: 10.3390/ijms241411701.


References
1.
Golledge J, Muller J, Daugherty A, Norman P . Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006; 26(12):2605-13. DOI: 10.1161/01.ATV.0000245819.32762.cb. View

2.
Sun X, Ding X, Liang H, Zhang X, Liu S, Bing-Han . Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies. Stem Cell Res Ther. 2020; 11(1):214. PMC: 7268531. DOI: 10.1186/s13287-020-01730-7. View

3.
Golledge J, Moxon J, Singh T, Bown M, Mani K, Wanhainen A . Lack of an effective drug therapy for abdominal aortic aneurysm. J Intern Med. 2019; 288(1):6-22. DOI: 10.1111/joim.12958. View

4.
Choi E, Lee H, Shin I, Park J, Yun T, Youn H . Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus. Cell Transplant. 2015; 25(6):1193-206. DOI: 10.3727/096368915X689442. View

5.
Isenburg J, Simionescu D, Starcher B, Vyavahare N . Elastin stabilization for treatment of abdominal aortic aneurysms. Circulation. 2007; 115(13):1729-37. DOI: 10.1161/CIRCULATIONAHA.106.672873. View